AMRX (Amneal Pharmaceuticals) EPS (Basic): $0.39 (TTM As of Mar. 2026)

What is Amneal Pharmaceuticals EPS (Basic)?

Amneal Pharmaceuticals AMRX -0.49% 63 EPS (Basic) is $0.39 as of Mar. 2026. GuruFocus rates AMRX with a GF Score™ of 63/100 and a GF Value™ of $7.57 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Amneal Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $0.20. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.39.

Amneal Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was $0.19. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.38.

Amneal Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was $0.23. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.86.

During the past 12 months, Amneal Pharmaceuticals's average EPS without NRIGrowth Rate was 31.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 6.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Amneal Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 24.80% per year. The lowest was -42.40% per year. And the median was -12.00% per year.

Amneal Pharmaceuticals (NAS:AMRX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Amneal Pharmaceuticals EPS (Basic) Related Terms

Amneal Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals EPS (Basic) Chart

Amneal Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

0.07

-0.86

-0.48

-0.38

0.23

Amneal Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															0.04	0.07	0.01	0.11	0.20

63GF Score

Amneal Pharmaceuticals Inc AMRX

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Amneal Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Amneal Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(72.057	-	0)	/	313.367
	=	0.23

Amneal Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(62.256	-	0)	/	316.023
	=	0.20

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.39

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $0.39 mean?

Amneal Pharmaceuticals (AMRX) has a EPS (Basic) of $0.39 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Amneal Pharmaceuticals and its competitors.

Is Amneal Pharmaceuticals' EPS (Basic) too high?

Amneal Pharmaceuticals' current EPS (Basic) is $0.39. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Amneal Pharmaceuticals' EPS (Basic) compare to INDV and KNSA?

Amneal Pharmaceuticals' EPS (Basic) of $0.39 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Drug Manufacturers company?

A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current EPS (Basic) is $0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Amneal Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.57, compared to a current price of $17.24 — trading 127.7% above its estimated fair value. The current EPS (Basic) is $0.39. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current EPS (Basic) is $0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.24 is trading 127.7% above its estimated GF Value™ of $7.57. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

EPS (Basic): $0.39
GF Value™: $7.57 vs. price of $17.24 (127.7% above fair value)
GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies INDV KNSA LQDA SUPN HIMS BCRX PBH LNTH ANIP AMLX XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges 2DT:Germany

Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807

Website https://www.amneal.com

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

63GF Score

Get the complete analysis for AMRX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.24

Price

$7.57

GF Value

View AMRX Analysis

See EPS (Basic) data for all stocks →